Literature DB >> 19863497

Symptoms and quality of life in obese children and adolescents with non-alcoholic fatty liver disease.

K D Kistler1, J Molleston, A Unalp, S H Abrams, C Behling, J B Schwimmer.   

Abstract

BACKGROUND: Data on the quality of life (QOL) of children with non-alcoholic fatty liver disease (NAFLD) are needed to estimate the true burden of illness in children with NAFLD. AIM: To characterize QOL and symptoms of children with NAFLD and to compare QOL in children with NAFLD with that in a sample of healthy children.
METHODS: Quality of life and symptoms were assessed in children with biopsy-proven NAFLD enrolled in the NASH Clinical Research Network. PedsQL scores were compared with scores from healthy children. For children with NAFLD, between-group comparisons were made to test associations of demography, histological severity, symptoms and QOL.
RESULTS: A total of 239 children (mean age 12.6 years) were studied. Children with NAFLD had worse total (72.8 vs. 83.8, P < 0.01), physical (77.2 vs. 87.5, P < 0.01) and psychosocial health (70.4 vs. 81.9, P < 0.01) scores compared with healthy children. QOL scores did not significantly differ by histological severity of NAFLD. Fatigue, trouble sleeping and sadness accounted for almost half of the variance in QOL scores. Impaired QOL was present in 39% of children with NAFLD.
CONCLUSIONS: Children with NAFLD have a decrement in QOL. Symptoms were a major determinant of this impairment. Interventions are needed to restore and optimize QOL in children with NAFLD.

Entities:  

Mesh:

Year:  2009        PMID: 19863497      PMCID: PMC2807909          DOI: 10.1111/j.1365-2036.2009.04181.x

Source DB:  PubMed          Journal:  Aliment Pharmacol Ther        ISSN: 0269-2813            Impact factor:   8.171


  48 in total

Review 1.  Nonalcoholic fatty liver disease.

Authors:  Paul Angulo
Journal:  N Engl J Med       Date:  2002-04-18       Impact factor: 91.245

2.  Nonalcoholic steatohepatitis clinical research network.

Authors: 
Journal:  Hepatology       Date:  2003-02       Impact factor: 17.425

3.  Health-related quality of life in long-term survivors of pediatric liver transplantation.

Authors:  D E Midgley; T A Bradlee; C Donohoe; K P Kent; E M Alonso
Journal:  Liver Transpl       Date:  2000-05       Impact factor: 5.799

4.  Health-related quality of life of severely obese children and adolescents.

Authors:  Jeffrey B Schwimmer; Tasha M Burwinkle; James W Varni
Journal:  JAMA       Date:  2003-04-09       Impact factor: 56.272

5.  Health-related quality of life in children with hepatitis C acquired in the first year of life.

Authors:  Andreas Nydegger; Anshu Srivastava; Melissa Wake; Arnold L Smith; Winita Hardikar
Journal:  J Gastroenterol Hepatol       Date:  2008-02       Impact factor: 4.029

6.  Quality of life of children and adolescents after kidney or liver transplantation: child, parents and caregiver's point of view.

Authors:  S Manificat; A Dazord; P Cochat; D Morin; F Plainguet; D Debray
Journal:  Pediatr Transplant       Date:  2003-06

7.  Health-related quality of life in pediatric liver transplant recipients: A single-center study.

Authors:  John C Bucuvalas; Maria Britto; Susan Krug; Frederick C Ryckman; Harry Atherton; Maria P Alonso; William F Balistreri; Uma Kotagal
Journal:  Liver Transpl       Date:  2003-01       Impact factor: 5.799

8.  Quality of life in adults with nonalcoholic fatty liver disease: baseline data from the nonalcoholic steatohepatitis clinical research network.

Authors:  Kristin David; Kris V Kowdley; Aynur Unalp; Fasiha Kanwal; Elizabeth M Brunt; Jeffrey B Schwimmer
Journal:  Hepatology       Date:  2009-06       Impact factor: 17.425

9.  Pediatricians overestimate importance of physical symptoms upon children's health concerns.

Authors:  Hester J Loonen; Bert H H F Derkx; Anne M Griffiths
Journal:  Med Care       Date:  2002-10       Impact factor: 2.983

10.  Impact of hepatitis C virus infection on children and their caregivers: quality of life, cognitive, and emotional outcomes.

Authors:  James R Rodrigue; William Balistreri; Barbara Haber; Maureen M Jonas; Parvathi Mohan; Jean P Molleston; Karen F Murray; Michael R Narkewicz; Philip Rosenthal; Lesley J Smith; Kathleen B Schwarz; Patricia Robuck; Bruce Barton; Regino P González-Peralta
Journal:  J Pediatr Gastroenterol Nutr       Date:  2009-03       Impact factor: 2.839

View more
  33 in total

1.  Advances in hepatology: current developments in the treatment of hepatitis and hepatobiliary disease.

Authors: 
Journal:  Gastroenterol Hepatol (N Y)       Date:  2009-12

2.  Parental perceptions regarding lifestyle interventions for obese children and adolescents with nonalcoholic fatty liver disease.

Authors:  Ingrid Rivera Iñiguez; Jason Yap; Diana R Mager
Journal:  Paediatr Child Health       Date:  2014-05       Impact factor: 2.253

Review 3.  Clinical advances in pediatric nonalcoholic fatty liver disease.

Authors:  Jeffrey B Schwimmer
Journal:  Hepatology       Date:  2016-03-04       Impact factor: 17.425

4.  NASPGHAN Clinical Practice Guideline for the Diagnosis and Treatment of Nonalcoholic Fatty Liver Disease in Children: Recommendations from the Expert Committee on NAFLD (ECON) and the North American Society of Pediatric Gastroenterology, Hepatology and Nutrition (NASPGHAN).

Authors:  Miriam B Vos; Stephanie H Abrams; Sarah E Barlow; Sonia Caprio; Stephen R Daniels; Rohit Kohli; Marialena Mouzaki; Pushpa Sathya; Jeffrey B Schwimmer; Shikha S Sundaram; Stavra A Xanthakos
Journal:  J Pediatr Gastroenterol Nutr       Date:  2017-02       Impact factor: 2.839

5.  Evaluation of Quantitative Imaging Biomarkers for Early-phase Clinical Trials of Steatohepatitis in Adolescents.

Authors:  Nidhi P Goyal; Mary Catherine Sawh; Patricia Ugalde-Nicalo; Jorge E Angeles; James A Proudfoot; Kimberly P Newton; Michael S Middleton; Claude B Sirlin; Jeffrey B Schwimmer
Journal:  J Pediatr Gastroenterol Nutr       Date:  2020-01       Impact factor: 2.839

6.  Weight loss results in significant improvements in quality of life for patients with nonalcoholic fatty liver disease: A prospective cohort study.

Authors:  Elliot B Tapper; Michelle Lai
Journal:  Hepatology       Date:  2016-02-22       Impact factor: 17.425

7.  Clinical Practice Approach to Nonalcoholic Fatty Liver Disease by Pediatric Gastroenterologists in the United States.

Authors:  Warren L Shapiro; Elizabeth L Yu; Jennifer C Arin; Karen F Murray; Sabina Ali; Nirav K Desai; Stavra A Xanthakos; Henry C Lin; Naim Alkhouri; Reham Abdou; Stephanie H Abrams; Megan W Butler; Sarah A Faasse; Lynette A Gillis; Timothy A Hadley; Ajay K Jain; Marianne Kavan; Kattayoun Kordy; Peter Lee; Jennifer Panganiban; John F Pohl; Carol Potter; Bryan Rudolph; Shikha S Sundaram; Shivali Joshi; James A Proudfoot; Nidhi P Goyal; Kathryn E Harlow; Kimberly P Newton; Jeffrey B Schwimmer
Journal:  J Pediatr Gastroenterol Nutr       Date:  2019-02       Impact factor: 2.839

8.  In Children With Nonalcoholic Fatty Liver Disease, Cysteamine Bitartrate Delayed Release Improves Liver Enzymes but Does Not Reduce Disease Activity Scores.

Authors:  Jeffrey B Schwimmer; Joel E Lavine; Laura A Wilson; Brent A Neuschwander-Tetri; Stavra A Xanthakos; Rohit Kohli; Sarah E Barlow; Miriam B Vos; Saul J Karpen; Jean P Molleston; Peter F Whitington; Philip Rosenthal; Ajay K Jain; Karen F Murray; Elizabeth M Brunt; David E Kleiner; Mark L Van Natta; Jeanne M Clark; James Tonascia; Edward Doo
Journal:  Gastroenterology       Date:  2016-08-26       Impact factor: 22.682

9.  Pediatric Nonalcoholic Fatty Liver Disease: A Report from the Expert Committee on Nonalcoholic Fatty Liver Disease (ECON).

Authors:  Rohit Kohli; Shikha Sunduram; Marialena Mouzaki; Sabina Ali; Pushpa Sathya; Stephanie Abrams; Stavra A Xanthakos; Miriam Vos; Jeffrey B Schwimmer
Journal:  J Pediatr       Date:  2016-01-01       Impact factor: 4.406

Review 10.  The Progression and Natural History of Pediatric Nonalcoholic Fatty Liver Disease.

Authors:  Nidhi P Goyal; Jeffrey B Schwimmer
Journal:  Clin Liver Dis       Date:  2015-12-14       Impact factor: 6.126

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.